Literature DB >> 33413200

Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study.

Jiuping Zhang1, Xin Cheng1, Huihui Zhang1, Ping Xu2, Peiying Jin1, Xiaoyan Ke3.   

Abstract

BACKGROUND: There is limited evidence on the use of antipsychotics in patients with early-onset schizophrenia, which lags significantly behind the studies on adult patients' medication and has a large disparity from actual clinical needs. Hence, this study aims to analyse the status of the drug use and its changes for patients with early-onset schizophrenia in our ward and to provide references on clinical medications for children and adolescents with schizophrenia.
METHODS: The distribution of antipsychotics on the day of discharge and their changes over time were retrospectively analysed in our inpatient department from March 2012 to July 2019. Descriptive statistical methods and χ2 tests were carried out.
RESULTS: A total of 746 inpatients with early-onset schizophrenia were included. Among them, 99.3% of patients were prescribed atypical antipsychotic drugs, with 5.5% of patients prescribed typical antipsychotic drugs. The top five most commonly used antipsychotics were aripiprazole, olanzapine, risperidone, paliperidone and clozapine. Olanzapine and risperidone were used more frequently in men (P < 0.01), whereas aripiprazole was used less frequently (P < 0.01). Olanzapine and paliperidone were used more frequently in patients with adolescent-onset schizophrenia (AOS) (P < 0.05), and risperidone was used more frequently in patients with child-onset schizophrenia (COS) (P < 0.01). Multiple antipsychotics during hospitalization were prescribed in 23.1% of patients. The combination of aripiprazole and olanzapine was the most common in the AOS group, and the combination of risperidone and clozapine was the most common in the COS group. Before and after approval by the competent Chinese authorities, the use of paliperidone and aripiprazole tended to be stable.
CONCLUSION: Atypical antipsychotics have been increasingly valued and used clinically. The consideration of medications for patients with early-onset schizophrenia needs to include factors such as age, sex, and severity of illness, metabolism and cognitive function at baseline.

Entities:  

Keywords:  Children and adolescents; Drugs; Schizophrenia; Status of treatment

Year:  2021        PMID: 33413200      PMCID: PMC7791722          DOI: 10.1186/s12888-020-02962-w

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  45 in total

Review 1.  Schizophrenia and Psychosis: Diagnosis, Current Research Trends, and Model Treatment Approaches with Implications for Transitional Age Youth.

Authors:  Vivien Chan
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2017-04

Review 2.  Pharmacologic treatment of adolescent and child schizophrenia.

Authors:  Christopher M Young; Robert L Findling
Journal:  Expert Rev Neurother       Date:  2004-01       Impact factor: 4.618

3.  Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.

Authors:  T Scott Stroup; Tobias Gerhard; Stephen Crystal; Cecilia Huang; Zhiqiang Tan; Melanie M Wall; Chacku Mathai; Mark Olfson
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

4.  Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.

Authors:  Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

5.  Course of patients diagnosed as having schizophrenia during first episode occurring under age 18 years.

Authors:  M Schmidt; B Blanz; A Dippe; T Koppe; B Lay
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 6.  Neurocognition in first-episode schizophrenia: a meta-analytic review.

Authors:  Raquelle I Mesholam-Gately; Anthony J Giuliano; Kirsten P Goff; Stephen V Faraone; Larry J Seidman
Journal:  Neuropsychology       Date:  2009-05       Impact factor: 3.295

7.  Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.

Authors:  Yamin Zhang; Qiang Wang; Gavin P Reynolds; Weihua Yue; Wei Deng; Hao Yan; Liwen Tan; Chuanyue Wang; Guigang Yang; Tianlan Lu; Lifang Wang; Fuquan Zhang; Jianli Yang; Keqing Li; Luxian Lv; Qingrong Tan; Yinfei Li; Hua Yu; Hongyan Zhang; Xin Ma; Fude Yang; Lingjiang Li; Qi Chen; Wei Wei; Liansheng Zhao; Huiyao Wang; Xiaojing Li; Wanjun Guo; Xun Hu; Yang Tian; Hongyan Ren; Xiaohong Ma; Jeremy Coid; Dai Zhang; Tao Li
Journal:  J Clin Psychiatry       Date:  2020-03-24       Impact factor: 4.384

Review 8.  Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia.

Authors:  Nicole E MacKenzie; Chantel Kowalchuk; Sri Mahavir Agarwal; Kenya A Costa-Dookhan; Fernando Caravaggio; Philip Gerretsen; Araba Chintoh; Gary J Remington; Valerie H Taylor; Daniel J Müeller; Ariel Graff-Guerrero; Margaret K Hahn
Journal:  Front Psychiatry       Date:  2018-12-05       Impact factor: 4.157

9.  Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.

Authors:  Jari Tiihonen; Heidi Taipale; Juha Mehtälä; Pia Vattulainen; Christoph U Correll; Antti Tanskanen
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

10.  Developmental Contributions of Schizophrenia Risk Alleles and Childhood Peer Victimization to Early-Onset Mental Health Trajectories.

Authors:  Lucy Riglin; Gemma Hammerton; Jon Heron; Stephan Collishaw; Louise Arseneault; Ajay K Thapar; Barbara Maughan; Michael C O'Donovan; Anita Thapar
Journal:  Am J Psychiatry       Date:  2018-11-29       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.